Literature DB >> 3010203

Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity.

A P Heintz, N F Hacker, J S Berek, T P Rose, A K Munoz, L D Lagasse.   

Abstract

Between 1974 and 1984, 70 patients underwent primary cytoreductive surgery for ovarian carcinoma at the University of California at Los Angeles. During the period of January 1974 to December 1978, optimal cytoreduction was achieved in 56.4% of the patients. With increased experience, this figure improved to 87.1% in the period of January 1979 to December 1983. The most common morbidity associated with the procedure was fever and prolonged ileus. Bowel resection was required in 20% of the patients and was not associated with increased morbidity. More liberal use of the end-to-end anastomosis stapling device facilitated low colon reanastomosis without colostomy, which contributed to the improved patient acceptance.

Entities:  

Mesh:

Year:  1986        PMID: 3010203     DOI: 10.1097/00006250-198606000-00007

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  9 in total

1.  [Surgical therapy of ovarian cancer].

Authors:  A Pfleiderer
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344

2.  Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively?

Authors:  Azam-Sadat Mousavi; Marjan Moradi Mazhari; Mitra Modares Guilani; Fatemeh Ghaemmaghami; Nadereh Behtash; Setareh Akhavan
Journal:  World J Surg Oncol       Date:  2010-02-19       Impact factor: 2.754

3.  Diffusion-weighted magnetic resonance imaging evaluation of intra-abdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma.

Authors:  Mercedes Espada; Jose R Garcia-Flores; Mar Jimenez; Elena Alvarez-Moreno; Mar De Haro; Lucia Gonzalez-Cortijo; Gines Hernandez-Cortes; Vicente Martinez-Vega; Ricardo Sainz De La Cuesta
Journal:  Eur Radiol       Date:  2013-04-19       Impact factor: 5.315

4.  Preoperative [F]FDG PET/CT predicts recurrence in patients with epithelial ovarian cancer.

Authors:  Hyun Hoon Chung; Hyun Woo Kwon; Keon Wook Kang; Jae Weon Kim; Noh-Hyun Park; Yong-Sang Song; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2012-01-09       Impact factor: 4.401

5.  An audit of surgical treatment of ovarian cancer in a metropolitan health region. Association of Obstetricians and Gynaecologists of the North East Thames Region.

Authors:  C N Hudson; P Potsides; O M Curling
Journal:  J R Soc Med       Date:  1991-04       Impact factor: 18.000

6.  Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.

Authors:  W Kuhn; B Schmalfeldt; U Reuning; L Pache; U Berger; K Ulm; N Harbeck; K Späthe; P Dettmar; H Höfler; F Jänicke; M Schmitt; H Graeff
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

7.  Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies.

Authors:  J Akahira; T Inoue; T Suzuki; K Ito; R Konno; S Sato; T Moriya; K Okamura; A Yajima; H Sasano
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

8.  Evolution of surgery in advanced epithelial ovarian cancer in a dedicated gynaecologic oncology unit-seven year audit from a tertiary care centre in a developing country.

Authors:  Anupama Rajanbabu; Santhosh Kuriakose; Sheikh Zahoor Ahmad; Tejal Khadakban; Dhiraj Khadakban; R Venkatesan; D K Vijaykumar
Journal:  Ecancermedicalscience       Date:  2014-04-17

9.  Preoperative Lymphocyte-Monocyte Ratio Is a Predictor of Suboptimal Cytoreduction in Stage III-IV Epithelial Ovarian Cancer.

Authors:  Wankyu Eo; Hong-Bae Kim; Yong Joo Lee; Dong Soo Suh; Ki Hyung Kim; Heungyeol Kim
Journal:  J Cancer       Date:  2016-08-11       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.